HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
2 clinical trials · Condition
◉ Watch HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study (NCT06805812) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2023-05-01 |
| A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer (NCT04355520) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-07-01 |
Track HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.